AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06378359 — intervention group
Intervention type: OTHER
Intervention: Screening and decolonization for SA carriers with the 3 drug bundle
Description: nasal mupirocin, chlorhexidine gluconate (CHG) mouth rinse and CHG soap showers x 5 days and non-SA carriers receive 2 CHG pre-op showers
Study NCT06378359 — intervention group
Intervention type: OTHER
Intervention: No screening for SA
Description: All receive the 3 drug bundle, Nasal mupirocin, chlorhexidine gluconate (CHG) mouth rinse, and CHG body wash
Study NCT06378359 — intervention group
Intervention type: OTHER
Intervention: no screening
Description: giving pre-surgical patients the three drug decolonization bundle without screening
Study NCT06378359 — intervention group
Intervention type: OTHER
Intervention: Nasal povidone-iodine on surgery day plus 2 CHG pre-op showers without screening.
Description: Nasal povidone-iodine on surgery day plus 2 CHG pre-op showers without screening.
Study NCT06378359 — intervention group
Intervention type: OTHER
Intervention: Nasal alcohol gel on surgery day plus 2 CHG pre-op showers without screening
Description: Nasal alcohol gel on surgery day plus 2 CHG pre-op showers without screening
Study NCT06394232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eyecyte-RPE™
Description: Eyecyte-RPE™ is a suspension of hiPSCs (human induced Pluripotent Stem Cells) derived Retinal Pigment Epithelial Cells
Study NCT05109182 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Innersight3D
Description: Innersight3D generates a virtual interactive 3D model of the CT scan.
Study NCT05557513 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: STANDARD Q COVID-19 Ag Test
Description: Device Name: STANDARD Q COVID-19 Ag Test Manufactured by SD Biosensor, Inc., Korea~Purpose: To detect COVID-19 (Its manufacture specification sensitivity was at 84.97% and specificity 98.4%)
Study NCT05451823 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Post auriclar-frontal
Description: Frontal sensors will be applied with lead 1 at the center of the forehead; lead 2, 2.8 cm lateral to lead 1; and lead 3 at the temporal area between the lateral canthus and the hairline.~Post auriclar sensors will be applied to the same side of the face, with lead 1 approximately 2.5 cm medial to the mastoid area, post-auricularly next to the hairline. Lead 2 will be attached at the mastoid area and lead 3 will be attached on the same side at the temporal area between the lateral canthus and the hairline.
Study NCT05198102 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant novel coronavirus vaccine (CHO cells)
Description: At 12 months after the basic immunization (window period ± 3 months), 1 dose of recombinant novel coronavirus vaccine (CHO cells) is vaccinated.
Study NCT04891237 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10,000 MG01 + 10,000 T517
Description: Purified and polymerized with glutaraldehyde allergen extract, from a mixture of grasses (Phleum pratense, Holcus lanatus, Poa pratensis, Festuca pratensis, Lolium perenne and Dactylis glomerata) and Olea (Olea europaea), adsorbed on aluminum hydroxide. The other ingredients are: sodium chloride (0.9%), phenol (0.4%) and water for injections
Study NCT04891237 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 30,000 MG01 + 10,000 T517
Description: Purified and polymerized with glutaraldehyde allergen extract, from a mixture of grasses (Phleum pratense, Holcus lanatus, Poa pratensis, Festuca pratensis, Lolium perenne and Dactylis glomerata) and Olea (Olea europaea), adsorbed on aluminum hydroxide. The other ingredients are: sodium chloride (0.9%), phenol (0.4%) and water for injections
Study NCT04891237 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The same solution and presentation as the active treatment, but without active ingredients
Study NCT04630847 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplant
Description: FMT utilizing stool from first degree relatives
Study NCT05626790 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: All participants will join an exercise program that will last 20-30 minutes, 5 days a week for 4 weeks, especially targeting proximal stabilization. The exercise program is expected to take 20-30 minutes. Each exercise will be done in 3 sets. Each set will include 10 repetitions. In weight-bearing exercises, the participant will be asked to hold the position for 10 seconds.
Study NCT05626790 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: All participants will join an exercise program that will last 20-30 minutes, 5 days a week for 4 weeks, especially targeting proximal stabilization. The exercise program is expected to take 20-30 minutes. Each exercise will be done in 3 sets. Each set will include 10 repetitions. In weight-bearing exercises, the participant will be asked to hold the position for 10 seconds.
Study NCT05626790 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PNF Stretching
Description: In addition to the exercises, three different PNF stretching will be applied to the participants in the PNF stretching group for 4 weeks, 5 days a week.~1. Biceps: Flex-Add-ER repositioned half pattern~2. Brachioradialis: Flex-Abd-ER repositioned half pattern~3. Brachialis: Ext-Add-IR half pattern In the supine position, the physiotherapist will move the forearm to the end of the passive range of motion according to the direction of limitation. Secondly, participants will be asked to perform a submaximal isometric contraction of the target muscle with an emphasis on rotation for 10 seconds. After this contraction, participants will be asked to relax for 5 seconds. In the third phase, the elbow joint will be actively repositioned to the new range of motion, and the physical therapist will help to the patient to keep this position for an additional 10 seconds. This procedure will be repeated 10 times with a 10 secs resting period between two consecutive stretches.
Study NCT05626790 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged Stretching
Description: In addition to the exercises given to both of the groups, static stretching will be applied to the elbow flexors in 2 different positions for 4 weeks, 5 days a week. Participants will need to complete 5 sets of 1.5-minute stretching and 30-second rest periods for both of the two stretching positions listed below. The total duration of the stretches to be performed together with the rest periods will be 20 minutes.~1. In supine position, the shoulder will be positioned in 90° abduction and internal rotation, the forearm will be positioned in pronation, then the shoulder will be slowly extended. In this way, especially the Biceps Brachii and Brachioradialis muscles are expected to be stretched.~2. In supine position, the shoulder will be positioned in 90° abduction and maximum external rotation, and the forearm will be positioned in full supination. In this way, especially the brachialis muscle is expected to be stretched.
Study NCT05701306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG-115
Description: Orally once every other day(QOD) for 2 weeks and suspended for 1 week, 21 days as a cycle.
Study NCT05701306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG-2575
Description: Orally once a day (QD) for 21 days, 21 days as a cycle.
Study NCT04576650 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Summit System
Description: Surgical implantation of the Summit system (consisting of one or two Medtronic Activa(R) RC+S grids with wireless communication capabilities) for Safety and efficacy testing of the Medtronic Summit System.
Study NCT04949061 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culturally Adapted Cognitive Behavioral Intervention (CA-CBI)
Description: CA-CBI is an intervention based on Culturally Adapted Cognitive Behavioral Therapy (CA-CBT) which was developed by Devon Hinton. This trans-diagnostic intervention has a structured manual which can be culturally adapted and it will be used to decrease psychological distress and increase quality of life by targeting cognitive and behavioral changes.
Study NCT04949061 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Enhanced Treatment as Usual (ETA-U)
Description: Participants who receive ETAU will be provided a brief psychoeducation via online leaflets and will be informed about centers where they can receive free psychosocial support.
Study NCT04403568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursolic Acid
Description: Ursolic Acid 150mg
Study NCT04403568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: Curcumin 600mg
Study NCT05672420 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: umbilical cord derived mesenchymal stem cells
Description: umbilical cord derived mesenchymal stem cells, intravenous infusion
Study NCT04702698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peposertib
Description: Participants will receive single oral dose of Peposertib tablet under fasting (Treatment A) or fed (Treatment B) conditions.
Study NCT04702698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peposertib
Description: Participants will receive oral suspension dose of peposertib tablets under fasted condition (Treatment C) in either period 1, 2 or 3 of part 1.
Study NCT05031000 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: blood glucose measurement: POCT
Description: measurement of blood glucose concentration using 5 different POCT glucometer
Study NCT05031000 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: blood glucose measurement: reference
Description: measurement of blood glucose concentration using 2 different laboratory analyzer
Study NCT04522622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide
Description: 20 micrograms
Study NCT04522622 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: DXA,VFA, X-ray, HR-pQCT, 18-F NAF PET/CT
Description: All participants undergo DXA and VFA or X-ray scans 3 times during the study. Some participants (those connected to Herlev) are offered 18F NAF PET/CT scans at baseline and after 12 months and some participants (those connected to Odense University Hospital and Aalborg University Hospital) are offered HR-pQCT scans at baseline and after 12 months. The 18F-NAF PET/CT and HR-pQCT are optional, so it is not a must to have these procedures done to participate in the study.
Study NCT04818944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirofiban Hydrochloride
Description: Tirofiban Hydrochloride will be dosed for 24 hours post MT via continuous IV
Study NCT04818944 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline will be dosed for 24 hours post MT via continuous IV
Study NCT06465472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stiripentol Oral Capsule
Description: The target dose of stiripentol will be 50 mg/kg/day with a maximum dose of 3,000 mg/day. Patients allocated to the Stiripentol group will receive this treatment during the first 6 months, and in continuation up to 12 months.
Study NCT06465472 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Capsule
Description: Placebo capsules will be administered for the first 6 months. Then patients will switch to stiripentol over the 6- to 12-month period.
Study NCT06465472 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Urine samples collect
Description: Collections of urine over 24 hours and the first urine in the morning (spot urines) will be carried out. Urine collections will be performed either during hospitalizations, or at home if appropriate conditions are met.
Study NCT06465472 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Urine samples collect
Description: Collections of urine over 24 hours and the first urine in the morning (spot urines) will be carried out. Urine collections will be performed either during hospitalizations, or at home if appropriate conditions are met.
Study NCT06465472 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Blood samples collect
Description: Series of blood samples will be taken (serum pregnancy test, Primary Hyperoxaluria genetic characterization, clinical laboratory assessments, vitamin B6 dosage, plasma oxalate dosage, stiripentol pharmacokinetics)
Study NCT06465472 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood samples collect
Description: Series of blood samples will be taken (serum pregnancy test, Primary Hyperoxaluria genetic characterization, clinical laboratory assessments, vitamin B6 dosage, plasma oxalate dosage, stiripentol pharmacokinetics)
Study NCT06465472 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Kidney imaging
Description: Kidney imaging will be obtained. Renal ultrasounds will be compulsory for all patients.
Study NCT06465472 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kidney imaging
Description: Kidney imaging will be obtained. Renal ultrasounds will be compulsory for all patients.
Study NCT06465472 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Quality of Life questionnaires
Description: Kidney Disease Quality of Life Questionnaire : KDQOL-36 for patients ≥18 years of age at screening, and the Pediatric Quality of Life Inventory (PedsQL) including the generic and KF modules (parent and/or self-report versions) for patients \<18 years of age at screening.~EQ-5D: a standardized instrument consisting of a questionnaire and a visual analog scale pertaining to 5 dimensions. Scoring of the questionnaire is based on degrees of disability. Scoring of the visual analog scale is based on a visual scale ranging from 0 (worst imaginable health state) to 100 (best imaginable health state). Higher scores indicate better health status. The EQ-5D-5L questionnaire (will be utilized in patients ≥18 years of age at screening, and the EQ-5D-Y questionnaire will be utilized in patients \<18 years of age at screening, where available.
Study NCT06465472 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of Life questionnaires
Description: Kidney Disease Quality of Life Questionnaire : KDQOL-36 for patients ≥18 years of age at screening, and the Pediatric Quality of Life Inventory (PedsQL) including the generic and KF modules (parent and/or self-report versions) for patients \<18 years of age at screening.~EQ-5D: a standardized instrument consisting of a questionnaire and a visual analog scale pertaining to 5 dimensions. Scoring of the questionnaire is based on degrees of disability. Scoring of the visual analog scale is based on a visual scale ranging from 0 (worst imaginable health state) to 100 (best imaginable health state). Higher scores indicate better health status. The EQ-5D-5L questionnaire (will be utilized in patients ≥18 years of age at screening, and the EQ-5D-Y questionnaire will be utilized in patients \<18 years of age at screening, where available.
Study NCT05702008 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rabies Information Education and Communication Material
Description: The test group was administered the rabies IEC material available on the National Center for Disease Control (NCDC) website (https://ncdc.gov.in/index1.php?page=1\&ipp=All\&lang=1\&level=2\&sublinkid=502\&lid=428) in English and Hindi languages using a WhatsApp broadcast every 3 days for 30 days, in a cyclical manner. This material includes brochures, posters, short films, and informative documents designed to educate the general public about rabies prevention and post-exposure prophylaxis practices. Text messages, encouraging the participants to go through the material, were also a part of this intervention.
Study NCT05517629 — intervention group
Intervention type: OTHER
Intervention: It is an observational cross-sectional study
Description: It is an observational cross-sectional study
Study NCT04522622 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: DXA,VFA, X-ray, HR-pQCT, 18-F NAF PET/CT
Description: All participants undergo DXA and VFA or X-ray scans 3 times during the study. Some participants (those connected to Herlev) are offered 18F NAF PET/CT scans at baseline and after 12 months and some participants (those connected to Odense University Hospital and Aalborg University Hospital) are offered HR-pQCT scans at baseline and after 12 months. The 18F-NAF PET/CT and HR-pQCT are optional, so it is not a must to have these procedures done to participate in the study.
Study NCT04522622 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Bone biopsy
Description: All participants are invited to undergo a bone biopsy after 12 months, but it is not a must to have the procedure done to participate in the study.
Study NCT04522622 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone biopsy
Description: All participants are invited to undergo a bone biopsy after 12 months, but it is not a must to have the procedure done to participate in the study.
Study NCT04522622 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Cardiac tests
Description: All participants are invited to undergo 24-hour blood pressure measurements and pulse wave measurements at baseline and after 18 months, but it is not a must to have these procedures done to participate in the study.
Study NCT04522622 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cardiac tests
Description: All participants are invited to undergo 24-hour blood pressure measurements and pulse wave measurements at baseline and after 18 months, but it is not a must to have these procedures done to participate in the study.
Study NCT04522622 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood and urine samples and physical examination
Description: All participants must undergo a physical examination and deliver blood and urine samples in order to participate in the study.
Study NCT04522622 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood and urine samples and physical examination
Description: All participants must undergo a physical examination and deliver blood and urine samples in order to participate in the study.
Study NCT05341401 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide MMX
Description: Budesonide MMX is a second generator corticosteroid with prolonged colonic release used for management of ulcerative colitis
Study NCT05341401 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: It is a corticosteroid used as a standard therapy for management of ulcerative colitis
Study NCT04885985 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DEB catheter
Description: Trade name of DEB catheter: AcoArt Tulip (0.018) or AcoArt Litos (0.014)
Study NCT05839717 — intervention group
Intervention type: PROCEDURE
Intervention: Blood sampling
Description: A specific blood sampling will be performed in addition to the classical evaluations that are performed in routine practice
Study NCT04654026 — intervention group
Intervention type: DRUG
Intervention: Aspirin/Clopidogrel
Description: No intervention, only observational studies
Study NCT06629181 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: The researchers will conduct a 4-week intervention for the intervention group participants.~Technology Use Basic Information Training, MHRS and e-pulse Systems Usage Training Health literacy, mobile health application usage training Counseling Applications will be made at the end of the training
Study NCT05684549 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: Observational study, no intervention
Study NCT05518617 — intervention group
Intervention type: OTHER
Intervention: Positron Emission Tomography (PET) scan using DASB tracer
Description: DASB is a highly selective PET radioligand for serotonin transporter and is a reliable tool to investigate serotonin terminals and neurons.~The included Magnetic Resonance Imaging (MRI) sequences serve to provide additional information plus complement PET data.~To quantify dopaminergic pathology with \[123I\]FP-CIT SPECT,
Study NCT05007925 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intravascular Lithotripsy
Description: Localized peripheral intravascular lithotripsy
Study NCT04823676 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic composition
Description: Mixture of two Lactoplantibacillus plantarum strains (formerly Lactobacillus plantarum) and one Levilactobacillus brevis strain (formerly Lactobacillus brevis), in a maltodextrin carrier (E1400)
Study NCT04823676 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin (E1400, qs)
Study NCT05986123 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Topical cream Z for PIH
Description: The topical cream Z contain combination of niacinamide, arbutin, Scutellaria Baicalensis Root Extract, Centella Asiatica Extract and Camellia Sinensis Leaf Extract. Participants will used the topical cream twice daily for 20 weeks
Study NCT05251584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mupirocin
Description: Apply mupirocin ointments for prevention of peritoneal dialysis-related infection between 1 January 2021 to 31 December 2021
Study NCT05251584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gentamicin
Description: Apply gentamicin creams for prevention of peritoneal dialysis-related infection for 1 year start after 1 January 2022
Study NCT04758455 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: P53, Ki67 and Cyclin A IHC.
Description: P53, Ki67 and Cyclin A immunohistochemical staining of formalin-fixed paraffin-embedded specimens of Wilms' tumour.